# Perioperative Immunotherapy for NSCLC (ECTOP-1030)

> **NCT06572722** · PHASE2 · WITHDRAWN · sponsor: **Fudan University**

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Nivolumab
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06572722
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-09-01
- **Primary completion:** 2026-09-01
- **Final completion:** 2029-09-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** This trial has not been initiated
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06572722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06572722, "Perioperative Immunotherapy for NSCLC (ECTOP-1030)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06572722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*